Letter to the Editor. Brachyury as prognostic biomarker in chordoma

Restricted access

If the inline PDF is not rendering correctly, you can download the PDF file here.

Article Information

INCLUDE WHEN CITING Published online April 27, 2018; DOI: 10.3171/2017.9.JNS172108.

Disclosures The authors report no conflict of interest.

© AANS, except where prohibited by US copyright law.

Headings

References

  • 1

    Bettegowda CYip SLo SLFisher CGBoriani SRhines LD: Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival. Neuro Oncol 19:4054132017

  • 2

    Feng YZhang QWang ZYan BWei WLi P: Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis. Int J Clin Exp Pathol 8:826882752015

  • 3

    Hu YMintz AShah SRQuinones-Hinojosa AHsu W: The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival. Carcinogenesis 35:149114992014

  • 4

    Kilic NFeldhaus SKilic ETennstedt PWicklein DWasielewski Rv: Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer 47:108010852011

  • 5

    Kitamura YSasaki HKimura TMiwa TTakahashi SKawase T: Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis. J Neuropathol Exp Neurol 72:8168232013

  • 6

    Morgan TMKoreckij TDCorey E: Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9:2372492009

  • 7

    Otani RMukasa AShin MOmata MTakayanagi STanaka S: Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. J Neurosurg [epub ahead of print July 28 2017. DOI: 10.3171/2016.12.JNS161444]

  • 8

    Palena CRoselli MLitzinger MTFerroni PCostarelli LSpila A: Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. J Natl Cancer Inst 106:dju0542014

  • 9

    Pillay NPlagnol VTarpey PSLobo SBPresneau NSzuhai K: A common single-nucleotide variant in T is strongly associated with chordoma. Nat Genet 44:118511872012

  • 10

    Pinto FPértega-Gomes NPereira MSVizcaíno JRMonteiro PHenrique RM: T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res 20:494949612014

  • 11

    Pinto FPértega-Gomes NVizcaíno JRAndrade RPCárcano FMReis RM: Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. Oncotarget 7:28891289022016

  • 12

    Sarkar DShields BDavies MLMüller JWakeman JA: BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. Int J Cancer 130:3283372012

  • 13

    Shalaby AAPresneau NIdowu BDThompson LBriggs TRTirabosco R: Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod Pathol 22:99610052009

  • 14

    Shimamatsu SOkamoto THaro AKitahara HKohno MMorodomi Y: Prognostic significance of expression of the epithelial-mesenchymal transition-related factor brachyury in intrathoracic lymphatic spread of non-small cell lung cancer. Ann Surg Oncol 23 (5 Suppl 5):101210202016

  • 15

    Song WGobe GC: Understanding molecular pathways and targets of brachyury in epithelial-mesenchymal transition (EMT) in human cancers. Curr Cancer Drug Targets 16:5865932016

  • 16

    Stacchiotti SCasali PGLo Vullo SMariani LPalassini EMercuri M: Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 17:2112192010

  • 17

    Sun İGüdük MGüçyetmez BYapicier ÖPamir MN: Chordoma: immunohistochemical analysis of brachury. Turk Neurosurg [epub ahead of print] 2016

  • 18

    Wang KTian KWang LWu ZRen CHao S: Brachyury: a sensitive marker, but not a prognostic factor, for skull base chordomas. Mol Med Rep 12:429843042015

  • 19

    Wang XBLv GHLi JZou MX: Ki-67 index as a prognostic marker in chordomas: a systematic review of the literature. World Neurosurg 101:7827842017

  • 20

    Wei WZhang QWang ZYan BFeng YLi P: miR-219-5p inhibits proliferation and clonogenicity in chordoma cells and is associated with tumor recurrence. Oncol Lett 12:456845762016

  • 21

    Zhai YBai JGao HWang SLi MGui S: Clinical features and prognostic factors of children and adolescents with clival chordomas. World Neurosurg 98:3233282017

  • 22

    Zhang LGuo SSchwab JHNielsen GPChoy EYe S: Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. PLoS One 8:e758512013

  • 23

    Zou MXLv GHWang XBLi J: Prognostic biomarkers in spinal chordoma: a systematic review. J Neuropathol Exp Neurol 75:118411872016

  • 24

    Zou MXLv GHWang XBLi J: Factors predicting recurrence after resection of clival chordoma using variable surgical approaches and radiation modalities. Neurosurgery 81:E28E312017 (Letter)

  • 1

    Kelley MJShi JBallew BHyland PLLi WQRotunno M: Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma. Hum Genet 133:128912972014

  • 2

    Pillay NPlagnol VTarpey PSLobo SBPresneau NSzuhai K: A common single-nucleotide variant in T is strongly associated with chordoma. Nat Genet 44:118511872012

  • 3

    Wu ZWang KWang LFeng JHao STian K: The brachyury Gly177Asp SNP is not associated with a risk of skull base chordoma in the Chinese population. Int J Mol Sci 14:21258212652013

TrendMD

Cited By

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 112 112 12
Full Text Views 118 118 5
PDF Downloads 56 56 1
EPUB Downloads 0 0 0

PubMed

Google Scholar